Presentation is loading. Please wait.

Presentation is loading. Please wait.

Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA.

Published byEaster Preston Modified over 9 years ago

Similar presentations

Presentation on theme: "Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA."— Presentation transcript:

1 Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA E MEDICINA TROPICAL

2 Morbidity and prognostic factors in chronic Chagas cardiopathy Medical and Social Relevance  Clinical importance of cardiac form  High morbidity and lethality  Few specific studies concerning its management

3 Peculiarities  Low socioeconomic status (Lopes et al., 1995)  Advanced stimulus conduction disorders  Increased frequency of PVCs and worse prognosis (Guerrero et al., 1985)  Intracardiac nervous system denervation (Oliveira, 1985)  Myocardial fibrosis (Barreto et al., 1997)  Ventricular aneurysms (Bestetti & Muccillo, 1997)  Thromboembolism (Carod-Artal et al., 2005) Morbidity and prognostic factors in chronic Chagas cardiopathy

4 What is the incidence of ischemic cerebrovascular events in patients with Chagas cardiomyopathy? What is the effect of the left ventricular ejection fraction on the risk for ischemic cerebrovascular events? Morbidity and prognostic factors in chronic Chagas cardiopathy

5 Thromboembolism Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

6 Thromboembolism Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

7 Thromboembolism Variable Patients without events n(%) Patients with previous stroke/TIA n(%) p value NYHA classes I-II133(76)29(74).720 Anticoagulation therapy32 (18)21 (54)<.001 LVEF36.7 ± 12.936.1 ± 14.1.789 Apical aneurysms67 (39)28 (72)<.001 Apical thrombus16(9)14(36)<.001 Baseline Characteristics of a Cohort of 213 Patients with Chagas Cardiomyopathy Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

8 Thromboembolism Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

9 Thromboembolism Variable Hazard ratio Beta coeffcient 95%CIp value LVEF ≤ 35%3.2241.1761.04-9.96.042 LA vol index (ml/m 2 )1.0320.0321.01-1.07.049 Predictors of ischemic cerebrovascular events in the multivariate analysis Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

10 Thromboembolism Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

11 Thromboembolism Morbidity and prognostic factors in chronic Chagas cardiopathy J Neurol Sci. 2009;278:96-101

12 How is the right ventricle affected in Chagas cardiopathy? Morbidity and prognostic factors in chronic Chagas cardiopathy

13 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy J Am Soc Echocardiogr. 2002;15:1197-201

14 Right ventricular involvement VariableControlChagasicp S (cm/s)14.5 ± 0.513.9 ± 0.4.32 IVCTr(ms)90.2 ± 2.9106.5 ± 2.3.0003 e’(cm/s)18.8 ± 0.815.9 ± 0.7.014 a’(cm/s)14.1 ± 0.916.2 ± 0.8.096 e’/a’ (cm/s)1.4 ± 0.11.1 ± 0.1.004 Comparison of Doppler tissue imaging in the right ventricle free wall between 12 control participants and 18 chagasic patients with normal echocardiogram s, Systolic flow velocity wave; IVCTr, regional isovolumic contraction time; e, early expansion velocity wave; a, late expansion velocity wave. Morbidity and prognostic factors in chronic Chagas cardiopathy J Am Soc Echocardiogr. 2002;15:1197-201

15 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy J Am Soc Echocardiogr. 2002;15:1197-201

16 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2004;94:79-85

17 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2004;94:79-85

18 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2004;94:79-85

19 Right ventricular involvement Association between maximal velocity of the tricuspid regurgitation jet and involvement of the right ventricle Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2004;94:79-85 p < 0.00001 Max Vel TR (cm/s) Right ventricle

20 ` Right ventricular involvement Association between left ventricular diastolic diameter and the degree of right ventricular involvement 1: normal 2: mildly enlarged 3: moderately enlarged 4: severely enlarged Morbidity and prognostic factors in chronic Chagas cardiopathy RV 4 3 2 1 LVd 90 80 70 60 50 n= 43 n= 15 n= 9 n= 7 Int J Cardiol. 2004;94:79-85 p<0.002 (mm)

21 What are the prognostic consequences of right ventricular involvement in chronic Chagas cardiopathy ? Morbidity and prognostic factors in chronic Chagas cardiopathy

22 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2008;127:372-9

23 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2008;127:372-9

24 Total Survivors (n=114) Non- survivors (n=44) Hazard Ratio (95% CI)p Age (years)48.5 ± 12.3 48.5 ± 12.148.6 ± 13.01.0 (0.98–1.03)0.834 Male gender (n/%) 99 (63) 71 (62)28 (64)0.96 (0.51–1.79)0.895 NYHA class III–IV (n/%) 33 (21) 13 (11%)20 (45%)2.79 (2.03–3.83)0.001 Systolic BP (mm Hg) 112.7 ± 17.3 115.2 ± 16.7 106.2 ± 17.3 0.97 (0.95–0.98)0.002 Syncope (n/%)34 (22%) 18 (16%)16 (36%)1.91 (1.32–2.76)0.001 PVC (n/%)76 (48) 50 (44)26 (59)1.93 (1.33–2.79)0.001 LA diameter (mm)43.1 ± 7.4 41.3 ± 6.647.6 ± 7.21.12 ( 1.08–1.16)0.001 LVDd/BSA (mm/m2)38.5 ± 5.7 36.8 ± 4.842.7 ± 5.81.17 (1.12–1.23)0.001 LVEF (%)36.9 ± 12.5 40.8 ± 11.126.7 ± 9.80.89 (0.87–0.92)0.001 LV Tei index0.71 ± 0.24 0.67 ± 0.220.85 ± 0.2425.7 (6.56–100.5)0.001 E/A ratio1.6 ± 1.0 1.4 ± 0.82.2 ± 1.21.89 (1.43–2.49)0.001 Right ventricular involvement Baseline characteristics of the patients and parameters predictors of death in the univariate analysis Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2008;127:372-9

25 Hazard Ratio(95% CI)p NYHA classes III-IV 2.151.16-4.290.030 LVEF (%) 0.960.91-0.990.026 RV Tei index 5.751.69-19.510.005 Right ventricular involvement Multivariate analysis of clinical and Doppler echocardiographic variables predicting death in Chagas cardiomyopathy Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2008;127:372-9

26 Right ventricular involvement Morbidity and prognostic factors in chronic Chagas cardiopathy Int J Cardiol. 2008;127:372-9

27 Does Chagas etiology imply a poorer prognosis when compared to other cardiomyopathies? Morbidity and prognostic factors in chronic Chagas cardiopathy

28 Chagasic vs. Idiopathic Without known etiology Ischemic heart disease excluded by angiography HF: 38 Sudden death: 35 Thromboembolism: 4 Non-cardiac death: 3 Dilatation with ventricular dysfunction Dilated cardiomyopathy n=169 Chagasic n=125 Follow-up mean: 44 ± 30 months Deaths 80 Idiopathic n=44 Two positive serum test (IIF, IH, ELISA) Morbidity and prognostic factors in chronic Chagas cardiopathy

29 Chagasic vs. Idiopathic VariableHRIC 95% P NYHA class III-IV 2.551.25 – 5.190.010 LV EF 0.950.91 – 0.980.012 RV Tei index 5.95 1.73 – 20.390.005 LA volume 1.021.01 – 1.040.010 Chagas etiology 2.921.28 – 4.780.007 Morbidity and prognostic factors in chronic Chagas cardiopathy Independent predictors of cardiac events in cohort of 169 patients with dilated cardiomyopathy

30 Chagasic vs. Idiopathic Morbidity and prognostic factors in chronic Chagas cardiopathy p=0.001 p<0.001

31 Chagasic vs. Idiopathic Chagas cardiomyopathy was associated with worse survival when compared to IDC, independent of other clinical factors and echocardiographic parameters of poor prognosis in HF Morbidity and prognostic factors in chronic Chagas cardiopathy

32 Chagasic vs. Idiopathic p<0.001 Morbidity and prognostic factors in chronic Chagas cardiopathy

33 Clinical relevance What can be done? Morbidity and prognostic factors in chronic Chagas cardiopathy Multicentric studies Risk stratification Identification of high-risk patients Identification of measures that could modify cardiac damage, functional heart impairment and prognosis

34 Thank you! rochamoc@medicina.ufmg.br

35

Download ppt "Manoel Otávio da Costa Rocha UNIVERSIDADE FEDERAL DE MINAS GERAIS - FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE: INFECTOLOGIA."

Similar presentations

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies

CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University

Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
Azin Alizadehasl, MD. Sarcoidosis is a systemic inflammatory disease of unknown etiology, characterized by non-caseating granulomas. It mainly affects.

Azin Alizadehasl, MD. Sarcoidosis is a systemic inflammatory disease of unknown etiology, characterized by non-caseating granulomas. It mainly affects.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.

Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.

© Continuing Medical Implementation …...bridging the care gap Valvular Heart Disease Aortic Stenosis.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines HEART FAILURE Working Group: Alan D. Bell, MD, CCFP; James D.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines HEART FAILURE Working Group: Alan D. Bell, MD, CCFP; James D.
Diabetes Mellitus As a Risk Factor for Right Ventricular Dysfunction and Impact on Mortality by Zubair Shah, PGY-III Research Mentor: Dr. Yuji Saito, M.D.,

Diabetes Mellitus As a Risk Factor for Right Ventricular Dysfunction and Impact on Mortality by Zubair Shah, PGY-III Research Mentor: Dr. Yuji Saito, M.D.,
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.

Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Investigator Investigator: Sharma Kattel, MBBS Mentor: Mentor: Yuji Saito, MD, PhD, FACP, FACC Department of Internal Medicine Sisters of Charity Hospital.

Investigator Investigator: Sharma Kattel, MBBS Mentor: Mentor: Yuji Saito, MD, PhD, FACP, FACC Department of Internal Medicine Sisters of Charity Hospital.
Ventricular Diastolic Filling and Function

Ventricular Diastolic Filling and Function
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,

Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,
La selezione dei pazienti candidati alla Terapia Resincronizzante Cardiaca M Cristina Porciani Firenze “Incontri Pitagorici di Cardiologia 2010” “Πυθαγόρειοι.

La selezione dei pazienti candidati alla Terapia Resincronizzante Cardiaca M Cristina Porciani Firenze “Incontri Pitagorici di Cardiologia 2010” “Πυθαγόρειοι.
Role of MRI in TOF follow-up TOF symposium October 25, 2013 Dr Edythe Tham.

Role of MRI in TOF follow-up TOF symposium October 25, 2013 Dr Edythe Tham.
Working Group of Heart Failure and Cardiac Function How to evaluate and treat dyssynchrony ? P Lancellotti, LA Piérard, Liège, BE.

Working Group of Heart Failure and Cardiac Function How to evaluate and treat dyssynchrony ? P Lancellotti, LA Piérard, Liège, BE.
Diastolic Dysfunction is Common in Asymptomatic HIV Patients Priscilla Y. Hsue 1,2, Husam H. Farah 1,2, Ann F. Bolger 1,2, Swapna Palav 2, Samira Ahmed.

Diastolic Dysfunction is Common in Asymptomatic HIV Patients Priscilla Y. Hsue 1,2, Husam H. Farah 1,2, Ann F. Bolger 1,2, Swapna Palav 2, Samira Ahmed.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,

The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:

Similar presentations

Ads by Google